Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 9;9(17):4415-4424.
doi: 10.1182/bloodadvances.2024015659.

Symptoms, unmet needs, and quality of life in Erdheim-Chester disease: a longitudinal registry-based analysis

Priya H Marathe  1 , Anne S Reiner  2 , Dana Bossert  3 , Allison M Sigler  3 , Deanna Fournier  4 , Kathleen Brewer  5 , Gaurav Goyal  6 , Thomas M Atkinson  7 , Jun J Mao  8 , Katherine S Panageas  2 , Eli L Diamond  3   9
Affiliations

Symptoms, unmet needs, and quality of life in Erdheim-Chester disease: a longitudinal registry-based analysis

Priya H Marathe et al. Blood Adv. .

Abstract

Measurement of patient-reported outcomes (PROs) and health-related quality of life (HrQOL) are crucial for comprehensive, patient-centered cancer care. Both PROs and HrQOL have been understudied in patients with Erdheim-Chester disease (ECD), a rare cancer with protean manifestations, dense symptomatology, and frequent diagnostic delay. We sought to evaluate the longitudinal evolution of symptom burden and unmet supportive care needs in patients with ECD, and to identify associations between these PROs and HrQOL. A registry-based cohort of patients with ECD completed a PRO battery including the Functional Assessment of Cancer Therapy-General (FACT-G) and other validated PRO measures. Descriptive statistics were used to characterize the distribution of PROs and FACT-G scores; PROs were modeled by univariable linear regression with FACT-G total score as the dependent variable at (1) registry enrollment and (2) 12-month time points. Changes in FACT-G total score (the difference between the 12-month and enrollment scores) were correlated with changes in PROs using univariable linear regression analysis. In 158 patients, mean total FACT-G was 70.8, lower than observed across multiple cancer cohorts. Higher levels of pain and fatigue, presence of neurologic symptoms, and greater number of unmet needs were all associated with worse HrQOL. Improvement in pain, fatigue, and unmet needs over 12 months was significantly associated with improvement in HrQOL. In patients with ECD, HrQOL is substantially diminished, even when considering other patients with cancer. Mitigation of symptoms and addressing unmet supportive care needs represent opportunities for intervention to improve HrQOL in ECD.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: E.L.D. discloses unpaid editorial support from Pfizer Inc, and serves on an advisory board for Opna Bio, both outside the submitted work. G.G. reports consulting fee from Recordati; reports royalties from UpToDate; reports fees for advisory boards for Opna Bio, Seagen, and Sobi; and serves on an advisory board for SpringWorks Therapeutics. The remaining authors declare no competing financial interests.

Figures

None
Graphical abstract
See this image and copyright information in PMC

References

    1. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research. U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:79. - PMC - PubMed
    1. Go RS, Jacobsen E, Baiocchi R, et al. Histiocytic neoplasms, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(11):1277–1303. - PubMed
    1. Haroche J, Cohen-Aubart F, Amoura Z. Erdheim-Chester disease. Blood. 2020;135(16):1311–1318. - PubMed
    1. Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121(9):1495–1500. - PubMed
    1. Haroche J, Cohen-Aubart F, Arnaud L, et al. Erdheim-Chester disease [in French] Rev Med Interne. 2014;35(11):715–722. - PubMed